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Background: Multiple treatment strategies for subjects with high grade dysplasia (HGD) in Barrett’s
oesophagus (BO) have been suggested. However, it is unclear which of these strategies provides the
greatest life expectancy, and the costs associated with the management strategies are unknown.
Aim: To compare the efficacy and cost effectiveness of competing management strategies for BO with
HGD.
Methods: We created a decision analysis model in Data 4.0 to assess possible treatment strategies for BO
with HGD. The strategies included: (1) no preventative strategy, (2) elective surgical oesophagectomy, (3)
endoscopic ablation, and (4) surveillance endoscopy. The base case was a healthy 50 year old White
male with an initial diagnosis of BO with HGD. The model allowed for complications of surgery, including
death. Ablative therapy could cause stricture or perforation. Pathological misinterpretation was allowed,
and modelled after reported rates. Estimates were derived from the literature for the rate of progression of
HGD to cancer and for complication rates for the various treatment modalities. The endoscopic ablation
arm was modelled as photodynamic therapy. Sensitivity analyses were performed over a wide range of
cancer incidences, complication rates, and procedure costs.
Results: Endoscopic ablation was the most effective strategy, yielding 15.5 discounted quality adjusted life
years (dQALY), compared with 15.0 for endoscopic surveillance and 14.9 for oesophagectomy. No
preventative strategy was the most inexpensive option, yielding an average cost per quality adjusted life
year of $54 (J44) per dQALY, but resulted in high rates of cancer. Endoscopic surveillance dominated
oesophagectomy, being both less costly and more effective. The condition of extended dominance
occurred when comparing endoscopic ablation to endoscopic surveillance because, although the total
costs of ablation were greater than those of surveillance, it was less expensive to buy an additional life year
using endoscopic ablation than endoscopic surveillance. The incremental cost effectiveness ratio when
moving from no therapy to ablative therapy was a reasonable $25 621/dQALY (J21 009/dQALY).
Sensitivity analysis demonstrated that when yearly rates of progression to cancer from HGD exceeded
30%, oesophagectomy became the most cost effective option.
Conclusions: A strategy of endoscopic ablation provided the longest quality adjusted life expectancy for
BO with HGD. Although endoscopic surveillance was less expensive than endoscopic ablation, it was
associated with shorter survival. Optimal utilisation of healthcare resources may be achieved with
endoscopic ablative therapy for BO with HGD.
B
arrett’s oesophagus (BO), a metaplastic change of the
lining of the oesophagus from squamous to specialised
columnar, is associated with an increased risk of
adenocarcinoma of the oesophagus.1 However, few subjects
with BO actually go on to develop cancer, and the risk of
cancer in BO is thought to approximate 0.5% per year.2–5 The
single most predictive known variable for progression to
cancer in subjects with BO is the presence of dysplasia.
Subjects with no dysplasia have extremely low cancer rates
for the five years following the index endoscopy.6 Conversely,
subjects with high grade dysplasia (HGD) have rates reported
as high as 10% per year.7–10 Additionally, because endoscopic
biopsies are random, the risk of metachronous cancer in
subjects found to have BO with HGD is also high. Studies of
subjects who have had resection for BO with HGD show that
40% or more may have previously undetected adenocarci-
noma in their resection specimens.11–13
Because HGD represents a chance to intervene prior to the
development of cancer, care of this condition has been
debated. Some authorities, citing the high risk of metachro-
nous cancer and the relatively high rates of progression,
suggest oesophagectomy for those found to have BO with
HGD.11 13–15 Other investigators have adopted the approach of
watchful waiting, with frequent surveillance endoscopy in
the hope of detecting any cancers that do occur in an early
and resectable stage.8 Finally, innovations in endoscopic
therapy have allowed for the development of multiple
endoscopic ablative techniques designed to eradicate HGD
and metaplasia, with replacement by ‘‘neosquamous’’
epithelium.16–19 Which of these three approaches to BO with
HGD is most effective is unknown, and there are no
randomised controlled trials comparing the effectiveness of
ablative therapy, surgery, and endoscopic surveillance in the
setting of HGD.
When competing strategies offer trade offs between risks
and effectiveness, decision analysis models can be used to
compare the costs and outcomes associated with the various
strategies. The goal of this study was to develop a cost
Abbreviations: BO, Barrett’s oesophagus; HGD, high grade dysplasia;
dQALYs, discounted quality adjusted life years; PDT, photodynamic
therapy; ICER, incremental cost effectiveness ratio
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effectiveness model of the various competing strategies for
the management of BO with HGD. Through this model, we
wished to ascertain which of the three treatment strategies
provided the longest quality adjusted life expectancy and
which strategy was most cost effective. Our hypothesis was
that a minimally invasive endoscopic intervention might be
preferable to either intensive endoscopic surveillance or
surgery.
METHODS
We used Data 4.0 (TreeAge, Williamstown, Massachusetts,
USA) to develop a model simulating the three active
treatment strategies for BO with HGD (fig 1). The perspective
of the model was that of a third party payer. The base case
consisted of a 50 year old Caucasian male with symptoms of
reflux prompting endoscopy. Caucasian males are the
demographic group at highest risk for adenocarcinoma of
the oesophagus.20 21 Endoscopy demonstrates an appearance
consistent with BO, and no nodules or masses present in the
BO. Biopsies from this endoscopy demonstrated BO with




The intensive endoscopic surveillance protocol was modelled
after the recently described Hines Veteran’s Affairs Medical
Center protocol, which represents the longest published
follow up of a cohort of subjects with HGD.8 Endoscopic
surveillance consisted of four quadrant biopsies every 2 cm
along the length of visible Barrett’s epithelium, and occurred
every three months as long as HGD was detected, and for at
least one year. If no further HGD was detected in subsequent
surveillance, intervals were lengthened to every six months
for one year, then yearly thereafter. A finding of cancer on
any of these endoscopies led to oesophagectomy. Subjects
who did not develop cancer could die from competing causes
of mortality, or rarely, of complications related to surveillance
endoscopy. Surveillance endoscopy was presumed to be
terminated at death or age 80 years. In subjects under
surveillance who did develop cancer, the majority underwent
surgical oesophagectomy, with the remainder being unre-
sectable. Subjects with unresectable adenocarcinoma accrued
costs for palliative care and hospice, based on published rates.
Palliation consisted of oesophageal stenting and/or adminis-
tration of chemotherapy and radiation therapy.
The model allowed for misdiagnosis of histological speci-
mens, known to be common in the setting of BO.22–24 For
instance, a subject with true low grade dysplasia might be
misread as having cancer and would then undergo the
therapy for the diagnosed condition, not the actual condition.
In this way, subjects never developing true cancer might
suffer morbidity or mortality from complications of oesopha-
gectomy for a presumed cancer. Rates of misinterpretation of
histological specimens were derived from the published
literature.
Endoscopic ablative therapy
The endoscopic ablative therapy modelled was photodynamic
therapy (PDT).19 This therapy was modelled because it has
the most extensive reported experience in the literature.
Further details concerning this arm are discussed below.
Sensitivity analyses were performed to simulate both less
costly and less effective ablative therapies. In some cases,
multiple estimates for effectiveness were available. If data
were of similar quality, meta-analytic techniques were used
to combine reported results from case series to obtain
weighted estimates for effectiveness parameters. Often, data
failed tests of homogeneity, suggesting that combination of
the data would not be meaningful. In these cases, the largest
reported cohort with the longest follow up was used in the
base case, with sensitivity analysis used to simulate more
extreme data.
Surgical oesophagectomy
Morbidity and mortality associated with surgical oesopha-
gectomy were modelled based on published rates in the
literature. In our base case scenario, oesophagectomy was
assumed to have been performed at a major medical centre
proficient in the procedure. In sensitivity analyses, the higher
complication rates reported by community and low volume
centres were modelled.25–27
The model
The model is a hybrid model of a linear decision tree which
terminates in a Markov model for subjects not undergoing
oesophagectomy. Initially, subjects with a new diagnosis of
HGD are assigned to no preventative care or to undergo one
of the three treatment strategies (fig 1). Subjects assigned to
surgical oesophagectomy undergo their procedure, with the
associated morbidity and mortality. Those successfully
surviving their procedure are ‘‘cured’’ but live the remainder
of their life with the somewhat diminished utility of a post-
oesophagectomy patient (fig 2).
Subjects in the endoscopic ablation arm enter the decision
tree and undergo up to three attempts at endoscopic therapy
(fig 3). Ablative therapy has the potential to be ineffective, to
ablate all BO, or to ablate only HGD, leaving residual BO.
Ablative therapy may also lead to stricture formation or
perforation, with increasing risk of complications based on










Figure 1 General structure of the tree. Subjects with an initial diagnosis
of Barrett’s oesophagus with high grade dysplasia have four options
available to them: no surveillance or other preventative measures


















Figure 2 Structure of the surgery sub-tree. Subjects choosing surgery
may either survive or die from their resection. If they do survive, they may
still suffer major morbidity such as anastomotic leakage, postoperative
infection, or bleeding. Among those surviving, resection of Barrett’s
oesophagus may be complete or incomplete. ‘‘M’’ denotes entry into the
Markov model (see text for details).
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superficial cancers misdiagnosed as HGD may also be cured
through ablative therapy. In subjects developing strictures,
ablative therapy is halted, and the subject undergoes one or
more endoscopic dilatations to ameliorate symptoms of
dysphagia.28 They are then entered into the Markov model
for continued surveillance. Subjects who undergo three
sessions of ablative therapy without complete resolution of
their BO also enter the Markov model for endoscopic
surveillance. Ablative therapy that results in perforation
leads to oesophagectomy, with its associated morbidity and
mortality. In the base case scenario, even those who undergo
successful ablative therapy continue to undergo endoscopic
surveillance to assess for the development of malignancy in
or below the neosquamous epithelium.
Subjects assigned to endoscopic surveillance immediately
enter the Markov model and are allowed to transition to
different states based on published rates. Transitions are
made yearly, with patients redistributed to health states
based on the parameters in table 1. Figure 4 demonstrates the
Markov model. This part of the model is a modification of a
previously described model.29
Transition rates from HGD to cancer, as well as transitions
between other states demonstrated in fig 4, were modelled
after transitions reported in the English language literature.
Because some subjects who develop adenocarcinoma do so
without being previously diagnosed with HGD, transitions
from LGD to cancer and no dysplasia to cancer were also
allowed. Regression of dysplasia (HGD to LGD or no
dysplasia, LGD to no dysplasia) was also modelled.
Estimates for rates of transitions, as well as the utilities used
in the model, are shown in table 1. Ranges used for sensitivity

























Figure 3 Structure of the endoscopic ablation sub-tree. Subjects
choosing endoscopic ablation may have either complete or incomplete
ablation of their Barrett’s oesophagus. Whether ablation is complete or
incomplete, subjects may develop strictures from their ablative therapy.
Additionally, some subjects may develop a perforation of the
oesophagus from their therapy. Note that subjects developing strictures
receive no further attempts at ablative therapy and instead are given
serial dilatation, then entry into endoscopic surveillance, denoted here
with an ‘‘M,’’ for entry into the Markov model. Subjects who do not
suffer perforation or stricture, but have incomplete ablation, receive up to
two additional treatment sessions with ablative therapy.
Table 1 Model probability estimates and utilities
Variable Value Range Reference
Annual rate of progression of:
No dysplasia to cancer 0.005 0.001–0.1 2–5 41
Low grade dysplasia to cancer 0.025 0.005–0.05 41
High grade dysplasia to cancer 0.025 0.001–0.3 8 9 41–43
No dysplasia to high grade dysplasia 0.01 0.0028–0.083 8 42 44–46
Low grade dysplasia to high grade dysplasia 0.05 0.01–0.078 41 42 47 48
No dysplasia to low grade dysplasia 0.05 0.01–0.078 4 42 44 48 49
Annual rate of regression of:
No dysplasia to no Barrett’s 0.0175 0.001–0.02 50
Low grade dysplasia to no dysplasia 0.63 0.50–0.80 44 47
High grade dysplasia to no dysplasia 0.10 0.01–0.15 9 47
High grade dysplasia to low grade dysplasia 0.07 0.05–0.10 8 9 47
Treatment variables
Ablation causes stricture 0.185 0.10–0.30 19 51
Ablation causes perforation 0.003 0.001–0.01 19 51 52
Ablation eradicates all high grade dysplasia 0.88 0.5–1.0 19 51–55
Ablation eradicates all Barrett’s 0.40 0.1–0.5 19 51–55
Surgical resectability, cancer dx by surveillance 0.95 0.85–1 56–58
Surgical resectability, cancer dx symptomatically 0.50 0.1–0.7 57–59
Surgical mortality, cancer dx by surveillance 0.027 0.025–0.1 60–63
Surgical mortality, cancer dx symptomatically 0.05 0.025–0.43 59–62
Probability of major surgical morbidity 0.15 0.05–0.50 64–67
Surgery cures cancer, cancer dx by surveillance 0.80 0.6–0.9 8 15 57 58 68
Surgery cures cancer, cancer dx symptomatically 0.20 0.1–0.43 57–59 68
Death from endoscopy 0.000021 0–0.00005 69–72
Other major complication, endoscopy 0.0013 0–0.005 69–72
Mortality from surgery to repair perforation 0.08 0.05–0.15 28 73–76
Major morbidity from surgery to repair perforation 0.20 0.10–0.40 73 76
Misdiagnosis rates of dysplastic states
Cancer called high grade dysplasia 0.175 0.01–0.20 22 23 30 77
Cancer called low grade dysplasia 0.05 0.01–.10 22 23 30 77
High grade dysplasia called cancer 0.11 0.01–0.20 22 24 30 77
High grade dysplasia called low grade dysplasia 0.115 0.01–0.20 22 24 30 77
Low grade dysplasia called high grade dysplasia 0.083 0.01–0.10 24 30 77
Low grade dysplasia called cancer 0.05 0.01–0.10 24 30 77
Utilities
Barrett’s oesophagus 1.0 0.79–1.0 30*
Oesophagectomy 0.97 0.46–1.0 30 31
Cancer 0.50 0–1.0 29*
*Utilities derived from 56 surveillance eligible patients at Durham VA Medical Center.
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The primary outcome of the analysis was the incremental
cost effectiveness ratio (ICER). This figure represents the
additional cost per life year saved when one moves from one
strategy to another more effective, but more costly, strategy.
We also sought to define the overall most effective strategy
(that is, the strategy that provided the longest life expectancy
regardless of cost) and mean cost per subject for each
strategy.
Utili ty data
Patient preferences for living in various conditions were
adjusted with utilities. This method allows subjects with
disease to weight their preferences for living in a compro-
mised health state, such as being status post-oesophagect-
omy, when compared with living in perfect health. Health
utilities range from 1 (perfect health) to 0 (death). Utilities
were derived from two sources. Utilities for living post-
oesophagectomy have been previously reported.30 31 Utilities
for living in states of endoscopic surveillance were derived
from 56 veterans with BO undergoing endoscopic surveil-
lance at the Durham Veterans’ Affairs Medical Center. These
surveillance eligible patients were asked to rate quality of life
using a visual analogue scale, after reading a one paragraph
scenario describing life in that disease state. These subjects
were then asked to rate the quality of life that they would
assign to survival in that disease state.
Cost data
Costs, not charges, were used to compute cost effectiveness in
this model. Cost data were derived from the Centers for
Medicare and Medicaid Services of the US government
(formerly the Health Care Financing Administration) and
from published data (http://www.cms.hhs.gov/providers/
pufdownload/carrpuf.asp). Diagnosis related group data and
current procedure terminology codes were used to calculate
inpatient resource utilisation while outpatient costs were
calculated using ambulatory payment classification and
current procedure terminology codes. All costs are from the
perspective of a third party payer. Only direct health care
costs (medical costs incurred to produce the services
necessary to care for the patient) were included. Indirect
costs, such as lost income from work absence, and direct non-
health care costs (non-medical costs associated with health
care encounters) were not included in the model. Costs
estimates, along with a range of costs used for sensitivity
analysis, are listed in table 2. Costs and outcomes were
discounted at an annual rate of 3%.
RESULTS
In our baseline scenario, 50 year old subjects who receive no
preventative strategy for their BO with HGD live, on average,
13.90 discounted quality adjusted life years (dQALYs) and
accrue costs of $748 (J613) per patient. Endoscopic ablation
was the most effective strategy, yielding 15.5 dQALYs
compared with 15.0 for endoscopic surveillance and 14.9
for oesophagectomy. The average cost effectiveness, which
represents the lifetime cost of a given strategy divided by the
average life expectancy, was least if one pursued no
preventative strategy. Among the active strategies, endo-
scopic surveillance was the strategy associated with the
lowest average cost per dQALY, yielding a cost of $2321 per
dQALY (J1903/dQALY). Endoscopic surveillance also domi-
nated surgical oesophagectomy, being both less costly and
more effective. No preventative strategy led to almost 20% of
the patient population developing oesophageal adenocarci-
noma. The lifetime incidence of adenocarcinoma was cut
markedly by all three preventative strategies, with oesopha-
gectomy providing the least risk of cancer. Table 3 shows the
results of the base case analysis.
When comparing the strategy of endoscopic surveillance to
that of endoscopic ablation, the model demonstrated that
endoscopic ablation was superior to endoscopic surveillance
in a relationship known as ‘‘extended dominance’’.32 In
extended dominance, although one strategy is more expen-
sive than another, the prolonged life expectancy associated
with the more expensive strategy actually makes it cheaper to
buy a quality adjusted life year of additional survival using












Figure 4 The Markov model. Subjects who choose endoscopic
surveillance, as well as those who choose no preventative strategy, enter
the Markov model. Circles in the Markov model represent the disease
states that are possible for subjects in the model. The arrows represent
allowed transitions in the model. The rates at which subjects transition
through the states are different for those who undergo endoscopic
surveillance and those who do not. Note that transitions are allowed
from greater to lesser degrees of dysplasia. The schematic is a simplified
version of the much more complex model (.7000 nodes) because the
actual model includes states of misdiagnosis (for example, low grade
dysplasia diagnosed as high grade dysplasia). LGD, low grade
dysplasia; HGD, high grade dysplasia; S/P, status post.
Table 2 Model cost estimates
Variable Value ($ (J)) Range ($ (J)) Reference
Completed ablation therapy 20 000 (16 400) 10 000–30 000 (8200–24 600) 30 77*
Endoscopy with biopsies 830 (681) 350–1200 (287–984) 30 34 77*
Repair of oesophageal perforation 19 000 (15 580) 10 000–40 000 (8200–32 800) 30 77*
Endoscopic palliation of unresectable
cancer
2000 (1640) 1000–5000 (820–4100) 30 77
Surgical oesophagectomy 19 000 (15 580) 10 000–40 000 (8200–32 800) 30 34 77*
Care of incurable cancer 34 000 (27 880) 10 000–50 000 (8200–41 000) 30 77*
Clinic visit 50 (41) 25–100 (21–82) 30 77*
Total care of ablation related stricture 2490 (2042) 900–3000 (738–2460) 30 77*
*Centers for Medicare and Medicaid Services, US government (formerly the Health Care Financing
Administration), 2001.
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our situation, the incremental cost effectiveness ratio (that is,
the cost to buy an extra dQALY), when one utilises
endoscopic surveillance instead of no preventative strategy,
is approximately $32 000 (J26 240) while the cost when one
uses endoscopic ablation instead of no preventative strategy
is only about $25 600 (J20 992). Therefore, even though
ablative therapy is more expensive per patient, it has the
highest return in life years per dollar and is therefore the
preferred strategy.
Sensitivity analyses
Sensitivity analysis allows for systematic variation of an
estimate in the model such that the results of the analysis can
be seen over a wide variety of values for any estimate. This
technique is especially useful in instances when an important
estimate is either poorly described in the literature or has
widely divergent estimates. One way sensitivity analysis
refers to varying the value of one variable over a range to see
the effect of that variable on the cost effectiveness of the
strategies. Two way sensitivity analysis refers to the
simultaneous variation of two variables.
We performed one way sensitivity analysis on key variables
included in the model, varying estimates by the ranges noted
in table 1. Several observations are of note. Firstly, the model
is sensitive to variation in the rate at which HGD progresses
to cancer (fig 5). As expected, when the risk of developing
cancer in HGD increases, doing no prevention becomes a
much less effective strategy. Also of note is a change in the
relationship of surgery to endoscopic surveillance as cancer
risk increases. In our base case, surveillance endoscopy
dominates surgical oesophagectomy, being both less costly
and more effective. However, as the yearly rate of cancer in
the setting of HGD rises, this relationship changes, such that
surgery becomes a more cost effective strategy. Are there any
conditions in which surgery is more effective than endoscopic
ablation? It is not until the yearly risk of cancer in the setting
of HGD exceeds 30% (a level which is unrealistically high
based on the majority of the published literature) that
surgery provides a greater life expectancy than endoscopic
ablation.






















748 (613) — 13.90 — 54 (44) — 185.4










Endoscopic ablation 41 998 (34 438) 7274 (5965) 15.51 0.55 2708 (2220) 25 621
(21 009)
31.6
Cost, total cost of the strategy over the lifetime of the patient.
Incremental cost, increased cost the strategy represents over the next least costly strategy over the lifetime of the patient.
Effectiveness, total life expectancy remaining for the patient if treated with that strategy, measured in discounted quality adjusted life years (dQALY).
Incremental effectiveness, increased effectiveness the strategy represents over the next least effective strategy.
Incremental cost effectiveness ratio (ICER), incremental cost divided by the incremental benefit. Represents the additional cost associated with ‘‘buying’’ an
additional quality adjusted life year when moving from one less effective strategy to a more effective one.





























Figure 5 One way sensitivity analysis of effectiveness versus the
probability (Prob) that high grade dysplasia (HGD) turns into cancer
(CA). The yearly probability that Barrett’s oesophagus with HGD
develops into cancer is on the X axis, and the effectiveness of the given
strategies, measured in discounted quality adjusted life years, is on the Y
axis. As the annual likelihood of cancer rises, the effectiveness of the no
preventative strategy plummets. The effect on the surgical strategy is
negligible as all subjects undergo initial oesophagectomy. It is not until
the yearly risk of cancer tops 30%, an unrealistically high estimate, that
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Figure 6 One way sensitivity analysis of cost of ablative therapy versus
average cost effectiveness. As the cost of ablative therapy declines, it
becomes the strategy yielding the best average cost effectiveness. When
total costs (including drug costs, procedure costs, and follow up
endoscopic examinations in the immediate post ablation period) are less
than $15 000, the average cost effectiveness of ablation is superior to all
other active strategies. BO, Barrett’s oesophagus; HGD, high grade
dysplasia.
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How inexpensive does ablative therapy need to be to supply
the best average cost effectiveness of the three active
strategies? Figure 6 demonstrates the cost effectiveness of
the strategies as the cost of ablation is varied. The total costs
of ablative therapy must be less than $15 000 (J12 300) for
ablative therapy to surpass endoscopic surveillance and yield
the best average cost effectiveness of the active strategies.
Most other techniques for endoscopic ablative therapy are
less expensive than PDT. However, some of these may also be
less effective in the eradication of HGD. We performed a two
way sensitivity analysis simultaneously varying both the cost
and effectiveness of ablative therapy in obliterating HGD. The
results are shown in fig 7. Even under very unfavourable
conditions, with ablative therapy being quite expensive and
not very effective, the cost effectiveness of ablation as a
strategy still remains favourable. Even when ablation costs
$30 000 (J24 600), and 50% of cases have residual HGD after
ablation, the incremental cost effectiveness of endoscopic
ablation compared with no preventative strategy remains
under $40 000 (J32 800). Healthcare measures associated
with ICERs of less than $50 000 (J41 000) are generally
considered cost effective.33
In addition to standard expected value analysis of the
model, we performed a Monte Carlo simulation of the model.
This analysis, which simulated a randomised controlled trial
enrolling 1000 patients, demonstrated that in greater than
95% of simulations, the incremental cost effectiveness ratio of
ablative therapy had an ICER of less than $50 000 (J41 000)
when compared with no screening or surveillance.
Finally, we performed a ‘‘tornado analysis’’ of key and
poorly understood variables in the model. ‘‘Tornado analysis’’
is a way to visually describe how variation in any one input
over a clinically relevant range impacts the cost effectiveness
of the entire model. In such an analysis, the variability in the
incremental cost effectiveness ratio is demonstrated on the X
axis, and the key variables assessed are listed on the Y axis.
Figure 8 demonstrates the results of this analysis. As shown,
the variable to which the model was most sensitive was the
utility of living in the post-oesophagectomy state. Other key
variables, such as the probability of stricture formation or the
likelihood of residual HGD, have a lesser effect on the model.
DISCUSSION
Our model suggests that endoscopic ablative therapy provides
a longer quality adjusted life expectancy than either endo-
scopic surveillance or elective oesophagectomy for those with
BO and HGD. Ablative therapy avoids the large upfront costs
and considerable morbidity and mortality of surgery.
Additionally, unlike endoscopic surveillance, it prevents at
least some portion of those destined to develop cancer from
progressing to this costly state. Even if ablative therapy is
much less effective than has been reported in averting cancer,
the incremental cost effectiveness of this strategy still
remains well below $50 000 (J41 000) per quality adjusted
life year saved.
Although endoscopic surveillance was less expensive than
ablative therapy, it was also less effective. Because an
additional life year gained with endoscopic ablative therapy
is less expensive than a life year gained with endoscopic
surveillance, the model suggests that ablative therapy should
be the strategy of choice for most payers. This is especially
true when one considers that the model mandates continued
surveillance endoscopy for all subjects who undergo ablation,
whether or not it is successful. Continued endoscopic
surveillance in the ablation arm adds additional costs and
biases the model against ablation. The model was constructed
in this fashion to replicate current practice among those
performing ablation but further data may suggest that those
who undergo successful ablation do not require continued
surveillance. The model was further biased against endo-










































Figure 7 Two way sensitivity analysis of incremental cost effectiveness
versus the probability of residual high grade dysplasia (HGD) for three
different costs of ablative therapy. The probability that ablative therapy
leaves residual HGD is on the X axis. The incremental cost effectiveness
ratio, which is the cost to buy an additional year of discounted quality
adjusted life expectancy when changing from no preventative strategy to
endoscopic ablative therapy, is on the Y axis. Each line represents a
different total cost of ablative therapy. Even when ablative therapy is
very costly (that is, $30 000) and relatively ineffective (that is, 50% of
those receiving therapy still have residual HGD), the cost of an additional
year of life expectancy is relatively inexpensive (under $40 000). In
situations where ablative therapy may be both less costly but also less
effective (as may be the case with ablative modalities other than
photodynamic therapy), cost effectiveness ratios remain very favourable,























































Figure 8 ‘‘Tornado diagram’’ displaying changes in incremental cost
effectiveness over a range of plausible values for key variables. This
figure demonstrates the changes in the incremental cost effectiveness
ratio (ICER) of ablative therapy versus no intervention as multiple key
inputs are varied. Input variables are listed on the Y axis, along with the
clinically plausible ranges over which they were varied. The bars
represent the range in reported ICER for that range of the input variable.
Items near the ‘‘top’’ of the tornado (that is, utility of the post-oesophag-
ectomy state and cost of ablation) have a greater impact on the
performance of the model than those at the ‘‘bottom’’ of the tornado (that
is, probability of perforation and cost of care of a stricture). HGD, high
grade dysplasia; QALY, quality adjusted life years.
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oesophagectomies were done in high volume proficient
medical centres. Recent data suggest that results in smaller
lower volume centres are much less favourable.25–27
The presence of extended dominance of endoscopic
ablation over endoscopic surveillance has interesting ethical
implications. If a payer has limited resources, is it better to
give a select few subjects a more effective therapy (that is,
ablative therapy) or a larger number of patients a less
effective therapy (that is, endoscopic surveillance)? In this
case, from a utilitarian perspective, it would be logical to give
the smaller number of subjects the more effective therapy as
the overall life years gained per dollar spent is maximised
with this strategy. However, such rationing of healthcare is
neither palatable nor egalitarian. As healthcare dollars are
not limitless, and expensive therapies for many diseases
continue to proliferate, decisions such as which strategy to
use in BO with HGD will need to be considered in the larger
perspective of society’s willingness to pay for such treat-
ments.
This model has several important strengths. Unlike
previous decision analysis models of BO, this model allows
for histological misdiagnosis of specimens.30 34–36 Several
studies have recently demonstrated that there is substantial
variability in the diagnosis of BO histology.22–24 Also, the
model features utility estimates derived from actual subjects
with BO who are at risk of cancer, which were used for the
sensitivity analyses. This is superior to previous models which
rely on consensus of experts in the field for some estimates. It
is well demonstrated that physician estimates of quality of
life and preferences for survival in diminished states often
correlate poorly with patient preferences.37–40 Finally, the
model does not assume a linear progression through states of
dysplasia to cancer. Subjects may progress from no dysplasia
to cancer, or may in fact regress to lesser states of dysplasia,
as is seen in real world situations.
Important limitations of this model should also be
recognised. Several of the estimates used to construct the
model were based on relatively short term data. This is
especially true of the outcomes of PDT, for which only
relatively short term data are available. Extrapolating these
data to longer horizons may introduce inaccuracies in the
model. Also, there is variability in the reported rates of
multiple variables in the model. While we have attempted to
assess the effects of this variability on the model by means of
sensitivity analysis, the possibility remains that if multiple
estimates are extremely inaccurate, the model results may be
inaccurate. Next, our model concentrates on Caucasian
males, the group most likely to develop adenocarcinoma of
the oesophagus. Whether the results are generalisable to
other patient populations is unclear. Also, our utilities were
in part based on assessments from US veterans with BO,
using a visual analogue scale. The applicability of these
utilities to other populations is unclear. Finally, the model
assumes that the natural history of any given lesion will be
the same regardless of previous treatment. For instance,
those with HGD are assumed to have the same yearly risk of
cancer whether they were assigned directly to the endoscopic
surveillance arm or whether they initially underwent
unsuccessful PDT and were then placed in the surveillance
arm for their HGD after PDT failed. While this assumption is
pragmatically essential to create the model, the accuracy of
this assumption is not clear.
Perhaps the least well understood parameter in this study
is the rate at which HGD progresses to cancer. Some studies
have reported that one half or more of those patients
undergoing oesophagectomy for HGD will subsequently be
found to have carcinoma on the resection specimen.15 It is
important to note that such surgical studies actually
incorporate two sources of potential initial underdiagnosis
of cancer—there is a sampling error inherent in random
biopsies as well as a possibility of true progression of the
lesion to cancer in the time between endoscopy and resection.
In our model, we divided out the high risk of subsequent
cancer in HGD using two variables. Firstly, we allowed for a
generous sampling error rate, permitting as many as 20% of
true cancers to be ‘‘missed’’ at random biopsies and therefore
classified as lesser forms of dysplasia. Secondly, we also
modelled true progression of the lesion. While our baseline
rate of cancer progression was 2.5%, in sensitivity analyses
we allowed that rate to range as high as 30% per cycle. Of
note, we used data from a medical series8 showing a lower
rate of progression from HGD to cancer than most of the
surgical resection series. We chose to model these data in our
base case because they represented the longest term data
available on the largest cohort of HGD assembled, and
because the investigators were compulsive about excluding
prevalent cancers in their analysis.
A recent model assessing the potential effects of chemo-
prevention in BO with HGD arrived at similar conclusions to
the present study.36 The authors found that chemoprevention
with non-steroidal anti-inflammatory drugs for BO with
HGD would likely be highly cost effective, if we assume that
the preventative effects for cancer seen in epidemiological
studies of non-steroidal anti-inflammatory drug users would
be transmitted to those with BO. They concluded that any
manoeuvre that would result in reduction of cancer
occurrence in a group of high risk patients would likely be
superior to a strategy that relies on early detection of
developing cancers. The same phenomenon is noted in our
study, whereby patients receiving ablative therapy achieved
an improved life expectancy at a modest cost increase when
compared with endoscopic surveillance. The take home
message is that interventions that can potentially decrease
cancer incidence, even if expensive, will be likely be cost
effective compared with strategies that rely on decreasing
mortality from treatment of cancer that has already devel-
oped.
In summary, our model suggests that endoscopic ablative
therapy provides the longest quality adjusted life expectancy
in subjects with BO and HGD. Endoscopic surveillance has a
lower cost than endoscopic ablation but a condition of
extended dominance exists such that endoscopic ablation
will likely be the therapy of choice for most payers. Surgery is
dominated by endoscopic surveillance in the base case model,
and only becomes the favoured strategy at extremely high
rates of progression from HGD to cancer.
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Brown spots in the bowel
Question
Three patients underwent endoscopic examinations at our
institution for investigation of chronic anaemia. What is the
explanation for the endoscopic abnormalities seen in the
antrum (fig 1), distal duodenum (fig 2), and terminal ileum
(fig 3) from these three patients’ endoscopies?
See page 1763 for answer
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Figure 1 Antrum.
Figure 2 Distal duodenum.
Figure 3 Terminal ileum.
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